Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Viridian Therapeutics, Inc. Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease June 11, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences May 31, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Participate in Upcoming May Investor Conferences May 10, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results May 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 April 29, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference March 05, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer February 16, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock January 17, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock January 17, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference January 08, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease December 18, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference November 08, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology November 03, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing October 30, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease October 26, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors September 25, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September September 07, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 08, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) August 04, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 10, 2023 From Viridian Therapeutics, Inc. Via Business Wire Tickers VRDN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.